Herein we report the results of the KTS9 pilot study of 10 female patients with moderate to severe ME/CFS, treated with subcutaneous administration of the monoclonal anti-CD38 antibody daratumumab, targeting plasmablasts and long-lived plasma cells. Here, CD38 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.